Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ISO IsoPlexis (ISO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About IsoPlexis Stock (NASDAQ:ISO) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get IsoPlexis alerts:Sign Up Key Stats Today's Range$0.76▼$0.7650-Day Range$0.74▼$1.1352-Week Range$0.60▼$5.10VolumeN/AAverage Volume68,375 shsMarket Capitalization$30.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Read More… Receive ISO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter. Email Address ISO Stock News HeadlinesTruecaller earns triple ISO certificationsNovember 5, 2024 | prnewswire.comStandard BioTools Inc.: Standard BioTools Announces Senior Leadership ChangesAugust 2, 2024 | finanznachrichten.deFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.December 22, 2024 | Porter & Company (Ad)Diagnostic Industry Revelations: Comprehensive Analysis of Global Distribution Deals from 2016 to 2024 UnveiledMarch 5, 2024 | uk.finance.yahoo.comBruker to buy cell biology company PhenomeX for $108mAugust 18, 2023 | msn.comBruker Enters Functional Single-Cell Biology Research Solutions With PhenomeX AcquisitionAugust 17, 2023 | msn.comPhenomeX stock rallies by 137% after buyout offer from BrukerAugust 17, 2023 | msn.comBruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash TransactionAugust 17, 2023 | finance.yahoo.comSee More Headlines ISO Stock Analysis - Frequently Asked Questions How were IsoPlexis' earnings last quarter? IsoPlexis Co. (NASDAQ:ISO) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($10.66) EPS for the quarter, missing the consensus estimate of ($0.79) by $9.87. The company had revenue of $4.19 million for the quarter, compared to analyst estimates of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%. When did IsoPlexis IPO? IsoPlexis (ISO) raised $125 million in an IPO on Friday, October 8th 2021. The company issued 8,333,000 shares at a price of $14.00-$16.00 per share. What other stocks do shareholders of IsoPlexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that IsoPlexis investors own include Biora Therapeutics (BIOR), NIO (NIO), PayPal (PYPL), Alibaba Group (BABA), Robinhood Markets (HOOD) and Lucid Group (LCID). Company Calendar Last Earnings11/10/2021Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:ISO CUSIPN/A CIK1615055 Webisoplexis.com Phone203-208-4111FaxN/AEmployees459Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net Margins-632.41% Pretax Margin-632.40% Return on Equity-127.86% Return on Assets-71.41% Debt Debt-to-Equity Ratio1.12 Current Ratio4.06 Quick Ratio2.50 Sales & Book Value Annual Sales$16.76 million Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.73Miscellaneous Outstanding Shares39,760,000Free Float37,218,000Market Cap$30.28 million OptionableNot Optionable Beta1.32 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:ISO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thi...InvestorPlace | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IsoPlexis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share IsoPlexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.